What is Shanghai Shyndec Pharmaceutical Co., Ltd.'s (600420.SS) StockRank?

MoatMap's StockRank for Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) is 85/100, with a Strong Buy signal. This is a composite score combining Quality (63), Value (62), and Momentum (48) factor ranks across MoatMap's 19,000+ stock universe.

Does Shanghai Shyndec Pharmaceutical Co., Ltd. have an economic moat?

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Shanghai Shyndec Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) is Strong Buy, based on a StockRank of 85/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Shanghai Shyndec Pharmaceutical Co., Ltd. in?

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600420.SS

STRONG BUYREMOVE

Shanghai Shyndec Pharmaceutical Co., Ltd. · Healthcare · China · $1.8B · Avg Vol: $8M/d

StockRank

P/E (TTM)

15.9x

ROE

5.7%

D/E

0.0x

Dividend %

3.4%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Chinese pharmaceutical manufacturer focused primarily on the domestic market, lacking the global regulatory validation and high-end biologics capabilities of leading CDMOs.

COMPANY DESCRIPTION

Shanghai Shyndec Pharmaceutical, a subsidiary of China National Pharmaceutical Group (Sinopharm), specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. The company holds a leading position in anti-infective, cardiovascular, and endocrine therapeutic areas within China. Its integration into the massive Sinopharm distribution network provides a highly secure market channel and significant cost efficiencies.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	1.9B	1.8B	1.6B	1.4B	-10.3%
EPS	—	0.09	0.08	0.12	0.10	4.7%
Shares	—	1.0B	1.3B	1.3B	1.3B	+30.6%
Debt	229M	503M	169M	168M	6M	-59.3%
Equity	—	1.5B	1.8B	2.0B	2.0B	10.2%
Op CF	—	422M	254M	333M	251M	-15.9%
Inv CF	—	-45M	-201M	-127M	-353M	—
Fin CF	—	-64M	-162M	-61M	-243M	—

PRICE (1M)-12.4%

SMA 50SMA 200

$1.25

RSI (14)

34.5

52W High

$1.69

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

8.3%68.0

ROE

5.7%58.3

GP/Assets

13.5%32.3

Op. Margin

12.0%69.9

FCF/Assets

-4.9%36.2

Piotroski

—83.5

Int. Cover

50.0x91.4

D/E Ratio

0.00x95.6

Current Ratio

3.59x59.6

Value

P/E (TTM)

15.9x69.8

EV/EBITDA

6.5x53.5

P/FCF

—N/A

P/B

0.8x83.6

P/S

1.3x79.1

Div Yield

3.4%76.7

Momentum

52W High %

74%63.1

RS 6M

-24%49.5

SMA 50/200

0.92x39.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+91%69.5

Q Growth

-62%6.6

FUNDAMENTALS

Market Cap

$1.8B

P/E (Forward)

8.3x

Gross Margin

29.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600420.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600420.SS	Shanghai Shyndec Pharmaceutical Co., Ltd.(you)	$1.8B	85	STRONG BUY
605507.SS	Guobang Pharma Ltd.	$1.8B	88	STRONG BUY
600216.SS	Zhejiang Medicine Co., Ltd.	$1.8B	90	STRONG BUY
600993.SS	Mayinglong Pharmaceutical Group Co., Ltd.	$1.5B	88	STRONG BUY
600062.SS	China Resources Double-Crane Pharmaceutical Co.,Ltd.	$2.6B	88	STRONG BUY
002332.SZ	Zhejiang Xianju Pharmaceutical Co.,Ltd.	$1.2B	87	STRONG BUY
600867.SS	Tonghua Dongbao Pharmaceutical Co., Ltd.	$2.4B	90	STRONG BUY
600211.SS	Tibet Rhodiola Pharmaceutical Holding Co.	$1.8B	96	STRONG BUY
600267.SS	Zhejiang Hisun Pharmaceutical Co., Ltd.	$1.8B	95	STRONG BUY
600535.SS	Tasly Pharmaceutical Group Co., Ltd	$3.1B	86	STRONG BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.1%

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) — Stock Score Summary

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) has a MoatMap StockRank of 85/100 based on Quality (63/100), Value (62/100), and Momentum (48/100) factor scores. The current signal is STRONG BUY. Chinese pharmaceutical manufacturer focused primarily on the domestic market, lacking the global regulatory validation and high-end biologics capabilities of leading CDMOs.

Key Financial Metrics

Price	$1.25
Market Cap	$1.8B
P/E (TTM)	15.85
P/E (Forward)	8.31
Price/Book	0.82
Return on Equity	5.7%
Return on Invested Capital	8.3%
Debt/Equity	0.24
Gross Margin	29.3%
Operating Margin	12.0%
Revenue Growth	-20.8%
Dividend Yield	3.4%
Free Cash Flow	$-20M

Shanghai Shyndec Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Shanghai Shyndec Pharmaceutical Co., Ltd.’s (600420.SS) StockRank?: MoatMap’s StockRank for Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) is 85/100, with a Strong Buy signal. It is a composite of Quality (63), Value (62), and Momentum (48) factor ranks across MoatMap’s 19,000+ stock universe.
Does Shanghai Shyndec Pharmaceutical Co., Ltd. have an economic moat?: Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Shanghai Shyndec Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) is Strong Buy, based on a StockRank of 85/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Shanghai Shyndec Pharmaceutical Co., Ltd. in?: Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).